Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHR-2173 in Healthy Subjects
NCT06995001Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-2173 in systemic lupus erythematosus (SLE), lupus nephritis (LN), IgA nephropathy (IgAN) and 1 more (5 cohorts), sponsored by Hengrui Therapeutics. Primary endpoint: Treatment-emergent Adverse Events. Started Apr 2024; status: completed.
02
Drugs
SHR-2173
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)IgA nephropathy (IgAN)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06995001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995001.